Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction
Open Access
- 20 May 2020
- journal article
- research article
- Published by Wiley in ESC Heart Failure
- Vol. 7 (4), 1735-1743
- https://doi.org/10.1002/ehf2.12734
Abstract
Aims Reactive oxygen species are reportedly involved in the mechanism underlying heart failure with preserved ejection fraction (HFpEF); however, the disease pathophysiology remains poorly understood. Xanthine oxidoreductase (XOR), the rate‐limiting enzyme of purine metabolism, plays an important role in uric acid production and generates reactive oxygen species. However, the impact of plasma XOR activity on the clinical outcomes of patients with HFpEF remains unclear. The aim of this study was to investigate whether plasma XOR activity is associated with major adverse cardiovascular events (MACEs) in patients with HFpEF. Methods and results The plasma XOR activity was measured in 257 patients with HFpEF, who were then divided into three groups according to the activity levels: low XOR group (120 pmol/h/mL, n = 52). During the median follow‐up period of 809 days, there were 74 MACEs. Kaplan–Meier analysis revealed that the high XOR group was at the highest risk for MACEs. Multivariate analysis by Cox's proportional hazard regression approach showed that high XOR activity was significantly associated with MACEs, after adjustment for confounding factors. The patients were also divided into four groups according to the absence/presence of high XOR activity and/or hyperuricaemia. According to the multivariate Cox regression analysis, high XOR activity was associated with MACEs, regardless of the hyperuricaemia status. Conclusions Elevated plasma XOR activity is significantly associated with adverse clinical outcomes in patients with HFpEF.Keywords
Funding Information
- Sanwa Kagaku Kenkyusho Co., Ltd.
This publication has 36 references indexed in Scilit:
- Hyperuricemia and endothelial function: From molecular background to clinical perspectivesAtherosclerosis, 2018
- Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection FractionThe American Journal of Cardiology, 2017
- Heart Failure with Preserved Ejection FractionThe New England Journal of Medicine, 2016
- Pathophysiology of circulating xanthine oxidoreductase: New emerging roles for a multi-tasking enzymeBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2014
- New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypesEuropean Heart Journal, 2014
- A Novel Paradigm for Heart Failure With Preserved Ejection FractionJournal of the American College of Cardiology, 2013
- Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection FractionCirculation, 2012
- Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection FractionThe New England Journal of Medicine, 2006
- Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based StudyThe New England Journal of Medicine, 2006
- The Natural History of Congestive Heart Failure: The Framingham StudyThe New England Journal of Medicine, 1971